Hideaki Jinnouchi

Dr. Hideaki Jinnouchi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
NKNoboru Kurinami
Noboru Kurinami
SSSeigo Sugiyama
Seigo Sugiyama
AYAkira Yoshida
Akira Yoshida
KHKunio Hieshima
Kunio Hieshima
FMFumio Miyamoto
Fumio Miyamoto
HJHideaki Jinnouchi
Hideaki Jinnouchi

2 April 2015 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
HJHideaki Jinnouchi
Hideaki Jinnouchi
SSSeigo Sugiyama
Seigo Sugiyama
AYAkira Yoshida
Akira Yoshida
KHKunio Hieshima
Kunio Hieshima
NKNoboru Kurinami
Noboru Kurinami
TJTomio Jinnouchi
Tomio Jinnouchi
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreaticβ-cells. This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects. We investigated whether liraglutide, a GLP-1 analog, could enhance insulin sensitivity as assessed by the hyperinsulinemic-euglycemic clamp in type 2 DM patients.Materials. We prospectively enrolled 31 uncontrolled type 2 DM patients who were hospitalized and equally managed by guided diet- and exercise-therapies and then introduced to either liraglutide- or intensive insulin-therapy for 4 weeks. Insulin sensitivity was assessed by the glucose infusion rate (GIR) using hyperinsulinemic-euglycemic clamp before and after the therapies.Results. Values of HbA1c, postprandial plasma glucose, and body mass index (BMI) were significantly decreased by hospitalized intensive insulin-therapy or liraglutide-therapy. GIR was significantly increased by liraglutide-therapy but not by insulin-therapy, indicating that liraglutide-therapy significantly enhanced insulin sensitivity. BMI decreased during liraglutide-therapy but was not significantly correlated with changes in GIR. Multivariate logistic regression analysis demonstrated that liraglutide-therapy significantly correlated with increased insulin sensitivity in uncontrolled DM patients.Conclusions. Liraglutide may exhibit favorable effects on diabetes control for type 2 DM patients by increasing insulin sensitivity as an extrapancreatic action. Clinical trial registration Unique Identifier isUMIN000015201.

1 October 2016 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
NKNoboru Kurinami
Noboru Kurinami
SSSeigo Sugiyama
Seigo Sugiyama
AYAkira Yoshida
Akira Yoshida
KHKunio Hieshima
Kunio Hieshima
FMFumio Miyamoto
Fumio Miyamoto
HJHideaki Jinnouchi
Hideaki Jinnouchi

13 September 2013 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
KMKazunori Morita
Kazunori Morita
JSJunji Saruwatari
Junji Saruwatari
HMHaruna Miyagawa
Haruna Miyagawa
YUYoshihiro Uchiyashiki
Yoshihiro Uchiyashiki
KOKentaro Oniki
Kentaro Oniki
KNKazuko Nakagawa
Kazuko Nakagawa
Mitochondrial aldehyde dehydrogenase 2 (ALDH2) detoxifies reactive aldehydes in the micro- and macrovasculature. These substrates, including methylglyoxal and 4-hydroxynonenal formed from glucose and lipids, cause protein carbonylation and mitochondrial dysfunction, forming advanced glycation end products (AGEs). The present study aimed to confirm the association between the inactive ALDH2*2 allele and diabetic retinopathy (DR).

7 January 2017 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
HIHitoshi Ishii
Hitoshi Ishii
TNTetsuji Niiya
Tetsuji Niiya
YOYasuhiro Ono
Yasuhiro Ono
NINaoyuki Inaba
Naoyuki Inaba
HJHideaki Jinnouchi
Hideaki Jinnouchi
HWHirotaka Watada
Hirotaka Watada
Background: In addition to achieving good glycemic control, diabetes care management aims to improve the quality of life (QOL) in patients. Treatment-associated difficulties and side effects frequently cause deterioration in QOL. Liraglutide, a GLP-1 receptor agonist, is a novel injection drug that promotes insulin secretion. It is a user-friendly, once-daily injection with fewer hypoglycemic events. In this study, we aimed to examine the effect of liraglutide therapy on QOL in patients. Methods: In total, 304 insulin- and liraglutide-naïve patients with type 2 diabetes were enrolled in this observational study; they received liraglutide therapy for 12 weeks. The main outcome measure was change in QOL from baseline, which was assessed using diabetes therapy-related QOL (DTR-QOL). Results: At week 12, liraglutide significantly decreased HbA1c levels (8.7 ± 1.5 vs. 7.5 ± 1.3, p < 0.001) and BMI (27.9 ± 5.3 vs. 27.3 ± 5.2, p < 0.001). According to the QOL scores, although the treatment modality had changed from non-injection to injection therapy, liraglutide improved patient satisfaction with treatment. Significant correlations were found between change in HbA1c level and satisfaction with treatment, as well as between change in body weight and burden on social and daily activities, anxiety and dissatisfaction with treatment, and hypoglycemia. Conclusions: Liraglutide significantly improved glycemic control and reduced the body weight without deteriorating QOL in obese patients with type 2 diabetes. Trial registration UMIN-CTR: UMIN000007159

1 May 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
NKNoboru Kurinami
Noboru Kurinami
SSSeigo Sugiyama
Seigo Sugiyama
AMAyami Morita
Ayami Morita
AYAkira Yoshida
Akira Yoshida
KHKunio Hieshima
Kunio Hieshima
HJHideaki Jinnouchi
Hideaki Jinnouchi